0597 Hypoglossal Nerve Stimulation Adherence Increasing Yearly

Vikas Jain,Max Lundeen,Israel Byrd,Kent Lee,Michelle Um,Taye Allred
DOI: https://doi.org/10.1093/sleep/zsae067.0597
IF: 6.313
2024-04-20
SLEEP
Abstract:Abstract Introduction Hypoglossal nerve stimulation (HGNS) for obstructive sleep apnea is a surgically implanted device that the patient starts with a button press on a short-range telemetry remote. The therapy ends after a programmable time period (default 8 hours) or the patient manually stops the therapy with another button press. Patients newly implanted with Inspire devices have been observed to use their therapy more than patients implanted in the past. To test the effect of time on adherence, we analyzed newly activated HGNS patients’ usage data year by year. Methods De-identified data was collected via the manufacturer’s patient management system (SleepSync, Inspire medical systems). 8532 patients activated from 2018 through 2022 were selected. HGNS adherence was measured as total hours of therapy used per night via remote device uploads. Adherence during the patients’ first year was compared by year of device activation, using one-way analysis of variance (ANOVA) and Tukey’s test for multiple comparisons. Usage by activation year is reported as mean ± standard. Results In all patients, the mean pre-implant AHI and ESS were 34.3±15.2 and 9.4±4.9 respectively. Mean BMI and Age were 28.9±3.5 and 61.8±11.3 respectively. 2018 usage: 5.3±1.7 hrs, n=396. 2019 usage: 5.4±1.6 hrs, n=851. 2020 usage: 5.5±1.7 hrs, n=1426. 2021 usage: 5.5±1.6 hrs, n=2876. 2022 usage: 5.6±1.7 hrs, n=2983. ANOVA showed usage differed between at least two years (F=5.7, p< 0.001). Tukey analysis showed the mean patient adherence was significantly different between years 2018 and 2022 (95% CI=[-0.58, -0.08]), between 2019 and 2022 (95% CI=[-0.42, -0.06]), and between 2021 and 2022 (95% CI=[-0.27, -0.02]). Conclusion First-year HGNS adherence has increased over time, from 5.3 mean hours in 2018 to 5.6 mean hours in 2022. Iterative improvements in the Inspire Care Pathway over this time frame may have contributed to increased usage. Increasing device utilization is important especially in HGNS patients given their pre-baseline severities are in the moderate to severe range and increased utilization of therapy can lead to significant reductions in mean disease burden. Support (if any) Employees of Inspire Medical Systems contributed to the data analysis.
neurosciences,clinical neurology
What problem does this paper attempt to address?